

Péntek M.: Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of rheumatoid arthritis

## Appendix 8.2

### Search results and study selection

#### Search results for abatacept RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
<b>1: Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov;68(11):1708-14. Epub 2008 Dec 15. PubMed PMID: 19074911; PubMed Central PMCID: PMC2756956.</b>	<b>Incl: RCT</b>
<b>2: Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Helfrick R, Bathon J. Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009 Dec;68(12):1870-7. Epub 2009 Jan 5. PubMed PMID: 19124524; PubMed Central PMCID: PMC2770104.</b>	<b>Incl.: RCT</b>
3: Khraishi M, Russell A, Olszynski WP. Safety profile of abatacept in rheumatoid arthritis: a review. Clin Ther. 2010 Oct;32(11):1855-70. Review. PubMed PMID: 21095481.	excl.
4: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: Clin Exp Rheumatol. 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.	excl.
5: Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, Danneskiold-Samsøe B, Christensen R. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011 Jan;40(1):1-7. Epub 2010 Oct 15. Review. PubMed PMID: 20950126.	excl.
6: Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):297-300. Epub 2010 Oct 5. PubMed PMID: 20922440.	excl.: JIA
7: Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011 Mar;50(3):437-49. Epub 2010 Sep 28. Review. PubMed PMID: 20876701; PubMed Central PMCID: PMC3042254.	excl.
8: Gizinski AM, Fox DA, Sarkar S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol. 2010 Aug;24(4):463-77. Review. PubMed PMID: 20732645; PubMed Central PMCID: PMC3146352.	excl.
9: Finckh A. Comparative effectiveness of rheumatoid arthritis therapies. Curr Rheumatol Rep. 2010 Oct;12(5):348-54. PubMed PMID: 20652775.	excl.

References	Excl./Incl.
10: Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. <i>Ann Rheum Dis.</i> 2010 Oct;69(10):1768-73. Epub 2010 Jul 7. PubMed PMID: 20610444	excl.
11: Ruperto N, Lovell DJ, Li T, Sztajn bok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Alcala JO, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace C, Alessio M, Quartier P, Cortis E, Eberhard A, Simonini G, Lemelle I, Chalom EC, Sigal LH, Block A, Covucci A, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken).</i> 2010 Nov;62(11):1542-51. doi: 10.1002/acr.20283. Epub 2010 Jul 1. PubMed PMID: 20597110.	excl.:JIA
12: Dougados M, Wells G, Schmidely N, Le Bars M, van Riel P, Aletaha D, Schiff M, Smolen J. Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. <i>Clin Exp Rheumatol.</i> 2010 Mar-Apr;28(2):258-60. Epub 2010 May 13. PubMed PMID: 20483050.	excl.: RCT sub-analysis
13: Simon TA, Askling J, Lacaille D, Franklin J, Wolfe F, Covucci A, Suissa S, Hochberg MC; Abatacept Epidemiology Study Group. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. <i>Arthritis Res Ther.</i> 2010;12(2):R67. Epub 2010 Apr 14. PubMed PMID: 20398273; PubMed Central PMCID: PMC2888222.	excl.
14: Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. <i>Semin Arthritis Rheum.</i> 2010 Jun;39(6):425-41. Epub 2010 Mar 11. Review. PubMed PMID: 20223500.	excl.
15: Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. <i>Korean J Intern Med.</i> 2010 Mar;25(1):1-17. Epub 2010 Feb 26. Review. PubMed PMID: 20195397; PubMed Central PMCID: PMC2829405.	excl.
16: Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. <i>Arthritis Rheum.</i> 2010 Jun;62(6):1792-802. PubMed PMID: 20191582.	excl.: JIA
17: Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. <i>Curr Opin Rheumatol.</i> 2010 May;22(3):321-9. Review. PubMed PMID: 20190641.	excl.
18: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. <i>Drugs.</i> 2010;70(2):121-45.doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
19: Schiff M, Bessette L. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. <i>Clin Rheumatol.</i> 2010 Jun;29(6):583-91. Epub 2010 Jan 23. Review. PubMed PMID: 20099018.	excl.

References	Excl./Incl.
20: Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. <i>J Rheumatol.</i> 2010 Feb;37(2):234-45. Epub 2010 Jan 15. Review. Erratum in: <i>J Rheumatol.</i> 2010 Mar;37(3):682. PubMed PMID: 20080922.	excl.
21: Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Res Ther.</i> 2009;11(6):R163. Epub 2009 Nov 3. Review. PubMed PMID: 19886983; PubMed Central PMCID: PMC3003527.	excl.
22: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. <i>CMAJ.</i> 2009 Nov 24;181(11):787-96. Epub 2009 Nov 2. Erratum in: <i>CMAJ.</i> 2010 May 18;182(8):806. PubMed PMID: 19884297; PubMed Central PMCID: PMC2780484.	excl.
23: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. <i>J Manag Care Pharm.</i> 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
24: Hasegawa M, Imai Y, Hiraoka M, Ito K, Roy A. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. <i>J Pharmacokinet Pharmacodyn.</i> 2011 Dec;38(6):803-32. Epub 2011 Oct 15. PubMed PMID: 22002809.	excl.
<b>25: Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, Pappu R, Delaet I, Pans M, Ludivico C. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). <i>Ann Rheum Dis.</i> 2012 Jan;71(1):38-44. Epub 2011 Sep 13. PubMed PMID: 21917824; PubMed Central PMCID: PMC3233696.</b>	<b>incl.: RCT</b>
26: Schiff M, Keiserman M, Coddling C, Songcharoen S, Berman A, Nayiager S, Saldate C, Aranda R, Becker JC, Nys M, le Bars M, Reed DM, Poncet C, Dougados M. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. <i>Ann Rheum Dis.</i> 2011 Nov;70(11):2003-7. Epub 2011 Sep 12. PubMed PMID: 21914628; PubMed Central PMCID: PMC3184243.	excl.: open-label follow-up
27: Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, Li T, Zhou X, Becker JC, Aranda R, Peterfy C, Genant HK. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. <i>Ann Rheum Dis.</i> 2011 Oct;70(10):1826-30. PubMed PMID: 21893583; PubMed Central PMCID: PMC3171107.	excl.: RCT open-label follow-up
28: Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Moniz Reed D, Helfrick R, Westhovens R. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. <i>Ann Rheum Dis.</i> 2011 Nov;70(11):1949-56. Epub 2011 Aug 6. PubMed PMID: 21821865.	excl.: RCT open-label follow-up
29: Yazici Y, Moniz Reed D, Klem C, Rosenblatt L, Wu G, Kremer JM. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. <i>Clin Exp Rheumatol.</i> 2011 May Jun;29(3):494-9. Epub 2011 Jun 29. PubMed PMID: 21722499.	excl.
30: Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. <i>Clin Ther.</i> 2011 Jun;33(6):679-707. Review. PubMed PMID: 21704234.	excl.

References	Excl./Incl.
31: Papagoras C, Drosos AA. Abatacept: a biologic immune modulator for rheumatoid arthritis. <i>Expert Opin Biol Ther.</i> 2011 Aug;11(8):1113-29. Epub 2011 Jun 8. PubMed PMID: 21649536.	excl.
32: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. <i>Arthritis Res Ther.</i> 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
33: Brodszky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. <i>Orv Hetil.</i> 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
34: Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. <i>Rheumatology (Oxford).</i> 2012 Jan;51(1):60-8. Epub 2011 Apr 22. Review. PubMed PMID: 21515629.	excl.
35: Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. <i>Paediatr Drugs.</i> 2011 Jun 1;13(3):161-73. doi: 10.2165/11588140-000000000-00000. Review. PubMed PMID: 21500870.	excl.: JIA
36: Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. <i>Health Technol Assess.</i> 2011 Mar;15(14):1-278. Review. PubMed PMID: 21439251.	excl.
37: Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. <i>Curr Opin Rheumatol.</i> 2011 May;23(3):245-51. Review. PubMed PMID: 21427579.	excl.
38: Allaart CF, Huizinga TW. Treatment strategies in recent onset rheumatoid arthritis. <i>Curr Opin Rheumatol.</i> 2011 May;23(3):241-4. Review. PubMed PMID: 21346574.	excl.
39: Goldzweig O, Hashkes PJ. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. <i>Drug Des Devel Ther.</i> 2011 Jan 26;5:61-70. Review. PubMed PMID: 21340039; PubMed Central PMCID: PMC3038996.	excl.: JIA
40: Li T, Wells G, Westhovens R, Emery P, Becker JC, Tugwell P. Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. <i>Value Health.</i> 2011 Mar Apr;14(2):361-70. Epub 2011 Feb 5. PubMed PMID: 21296603.	excl. ?
41: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. <i>Pharmacotherapy.</i> 2011 Jan;31(1):39-51. PubMed PMID: 21182357.	excl.
42: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. <i>Sao Paulo Med J.</i> 2010;128(5):309-10. Review. PubMed PMID: 21181074.	excl.

### Search results for adalimumab RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
1: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. <i>J Manag Care Pharm.</i> 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
2: Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. <i>Clin Pharmacol Ther.</i> 2011 Dec;90(6):828-35. doi:10.1038/clpt.2011.256. Epub 2011 Nov 2. PubMed PMID: 22048227.	excl.
3: Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. <i>Ann Rheum Dis.</i> 2012 Feb;71(2):225-30. Epub 2011 Sep 29. PubMed PMID: 21960560.	excl.
4: Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. <i>J Rheumatol.</i> 2011 Oct;38(10):2169-71. Epub 2011 Aug 1. PubMed PMID: 21807781.	excl.: open-label study
5: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. <i>Arthritis Res Ther.</i> 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
6: Brodsky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. <i>Orv Hetil.</i> 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
7: Keystone EC. Does anti-tumor necrosis factor- $\alpha$ therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. <i>J Rheumatol.</i> 2011 Aug;38(8):1552-62. Epub 2011 May 15. Review. PubMed PMID:21572154.	excl.
8: Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. <i>Paediatr Drugs.</i> 2011 Jun1; 13(3):161-73. doi: 10.2165/11588140-000000000-00000. Review. PubMed PMID: 21500870.	excl.: JIA
9: Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. <i>Int J Immunopathol Pharmacol.</i> 2011 Jan-Mar;24(1):269-74. PubMed PMID: 21496415.	excl.
<b>10: van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. <i>Arthritis Rheum.</i> 2011 Jul;63(7):1782-92. doi: 10.1002/art.30372. PubMed PMID: 21452294.</b>	<b>incl: RCT</b>
11: Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. <i>Health Technol Assess.</i> 2011 Mar;15(14):1-278. Review. PubMed PMID: 21439251.	excl.
12: Hoff M, Kvien TK, Kälvesten J, Elden A, Kavanaugh A, Haugeberg G. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. <i>BMC Musculoskelet Disord.</i> 2011 Feb 27;12:54. PubMed PMID: 21352592; PubMed Central PMCID: PMC3053306.	excl.: RCT sub-analysis
13: Mackensen F, Lutz T. [Therapy for childhood uveitis: biologics: too often--too late?]. <i>Ophthalmologe.</i> 2011 Mar;108(3):213-21. Review. German. PubMed PMID: 21350869.	excl.

References	Excl./Incl.
14: Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. <i>J Rheumatol.</i> 2011 May;38(5):855-62. Epub 2011 Feb 1. PubMed PMID: 21285171.	excl.: open-label study
15: Soubrier M, Lukas C, Sibilica J, Fautrel B, Roux F, Gossec L, Patternotte S, Dougados M. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. <i>Ann Rheum Dis.</i> 2011 Apr;70(4):611-5. Epub 2011 Jan 17. PubMed PMID: 21242235; PubMed Central PMCID: PMC3048626.	excl.: RCT pooled analysis
16: Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilica J, Combe B. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. <i>J Rheumatol.</i> 2011 May;38(5):835-45. Epub 2011 Jan 15. PubMed PMID: 21239748.	excl.
17: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. <i>Pharmacotherapy.</i> 2011 Jan;31(1):39-51. PubMed PMID: 21182357.	excl.
18: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. <i>Sao Paulo Med J.</i> 2010;128(5):309-10. Review. PubMed PMID: 21181074.	excl.
19: Pope JE, Thorne C, Haraoui BP, Truong D, Psaradellis E, Sampalis JS. Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial. <i>Scand J Rheumatol.</i> 2011 May;40(3):232-3. Epub 2010 Nov 25. PubMed PMID: 21108544.	excl.
20: Silva LC, Ortigosa LC, Benard G. Anti-TNF- $\alpha$ agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. <i>Immunotherapy.</i> 2010 Nov;2(6):817-33. Review. PubMed PMID: 21091114.	excl.
21: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. <i>Clin Exp Rheumatol.</i> 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: <i>Clin Exp Rheumatol.</i> 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.	excl.
22: Sheno S, Wallace CA. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. <i>Paediatr Drugs.</i> 2010 Dec 1;12(6):367-77. doi: 10.2165/11532610-000000000-00000. Review. PubMed PMID: 21028916.	excl.: JIA
23: van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. <i>J Rheumatol.</i> 2010 Nov;37(11):2237-46. Epub 2010 Oct 1. PubMed PMID: 20889601.	excl.: open-label study
24: Pease C, Pope JE, Thorne C, Haraoui BP, Truong D, Bombardier C, Widdifield J, Psaradellis E, Sampalis JS, Bonner A. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. <i>J Rheumatol.</i> 2010 Dec;37(12):2469-74. Epub 2010 Sep 15. PubMed PMID: 20843910.	excl.
25: Finckh A. Comparative effectiveness of rheumatoid arthritis therapies. <i>Curr Rheumatol Rep.</i> 2010 Oct;12(5):348-54. PubMed PMID: 20652775.	excl.
26: Aerts NE, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS. T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis. <i>Clin Exp Rheumatol.</i> 2010 Mar-Apr;28(2):208-14. Epub 2010 May 13. PubMed PMID: 20483042.	excl.

References	Excl./Incl.
27: Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. <i>Pharmacotherapy</i> . 2010 Apr;30(4):339-53. Review. PubMed PMID: 20334454.	excl.
28: Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. <i>Semin Arthritis Rheum</i> . 2010 Jun;39(6):425-41. Epub 2010 Mar 11. Review. PubMed PMID: 20223500.	excl.
29: van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. <i>Arthritis Care Res (Hoboken)</i> . 2010 Feb;62(2):226-34. PubMed PMID: 20191522.	excl.: companion study to an RCT
30: Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R. [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009]. <i>Z Rheumatol</i> . 2010 Aug;69(6):561-7. German. PubMed PMID: 20174926.	excl.
31: Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. <i>Curr Dir Autoimmun</i> . 2010;11:180-210. Epub 2010 Feb 18. Review. PubMed PMID: 20173395.	excl.
32: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. <i>Drugs</i> . 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
33: De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, Galeazzi M. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. <i>Clin Rheumatol</i> . 2010 May;29(5):517-24. Epub 2010 Jan 16. PubMed PMID: 20082236.	excl.
34: Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Res Ther</i> . 2009;11(6):R163. Epub 2009 Nov 3. Review. PubMed PMID: 19886983; PubMed Central PMCID: PMC3003527.	excl.
35: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. <i>CMAJ</i> . 2009 Nov 24;181(11):787-96. Epub 2009 Nov 2. Erratum in: <i>CMAJ</i> . 2010 May 18;182(8):806. PubMed PMID: 19884297; PubMed Central PMCID: PMC2780484.	excl.
36: Köller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. <i>Rheumatology (Oxford)</i> . 2009 Dec;48(12):1575-80. Epub 2009 Oct 7. PubMed PMID: 19812228.	excl.
<b>37: Soubrier M, Puéchal X, Sibilía J, Mariette X, Meyer O, Combe B, Flipo RM, Mulleman D, Berenbaum F, Zarnitsky C, Schaeffer T, Fardellone P, Dougados M. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. <i>Rheumatology (Oxford)</i>. 2009 Nov;48(11):1429-34. Epub 2009 Sep 9. PubMed PMID: 19741011.</b>	<b>Incl.: RCT</b>

References	Excl./Incl.
38: Wiens A, Correr CJ, Venson R, Otuki MF, Pontarolo R. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. <i>Rheumatol Int.</i> 2010 Jun;30(8):1063-70. Epub 2009 Aug 26. Review. PubMed PMID: 19707765.	excl.
39: Peters MJ, Watt P, Cherry L, Welsh P, Henninger E, Dijkmans BA, McInnes IB, Nurmohamed MT, Sattar N. Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. <i>Ann Rheum Dis.</i> 2010 Sep;69(9):1687-90. Epub 2009 Jul 28. PubMed PMID: 19640853.	excl.

### Search results for certolizumab RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
1: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. <i>J Manag Care Pharm.</i> 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
2: Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. <i>Clin Pharmacol Ther.</i> 2011 Dec;90(6):828-35. doi:10.1038/clpt.2011.256. Epub 2011 Nov 2. PubMed PMID: 22048227.	excl.
3: Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. <i>Ann Rheum Dis.</i> 2012 Feb;71(2):225-30. Epub 2011 Sep 29. PubMed PMID: 21960560.	excl.
4: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. <i>Arthritis Res Ther.</i> 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
5: Brodsky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. <i>Orv Hetil.</i> 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
6: Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. <i>Arthritis Care Res (Hoboken).</i> 2011 Aug;63(8):1142-9. doi: 10.1002/acr.20481. PubMed PMID: 21485024.	excl.: RCT sub-analysis
7: Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. <i>Arthritis Rheum.</i> 2011 Aug;63(8):2203-8. doi:10.1002/art.30387. PubMed PMID: 21484766.	excl.: open-label study
8: Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. <i>Curr Opin Rheumatol.</i> 2011 May;23(3):245-51. Review. PubMed PMID: 21427579.	excl.
9: Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, Khanna D, Nikaï E, Coteur G, Schiff M. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Ann Rheum Dis.</i> 2011 Jun;70(6):996-1002. Epub 2011 Mar 17. PubMed PMID: 21415050; PubMed Central PMCID: PMC3086050.	excl.: RCT sub-analysis



References	Excl./Incl.
10: Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. <i>J Rheumatol</i> . 2011 Jun;38(6):990-6. Epub 2011 Mar 1. PubMed PMID: 21362764.	excl.: RCT sub-analysis
11: Mackensen F, Lutz T. [Therapy for childhood uveitis: biologics: too often--too late?]. <i>Ophthalmologe</i> . 2011 Mar;108(3):213-21. Review. German. PubMed PMID: 21350869.	excl.
12: Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ES, Fry-Smith A. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. <i>Cochrane Database Syst Rev</i> . 2011 Feb 16;(2):CD007649. Review. PubMed PMID: 21328299.	excl.
13: Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. <i>J Rheumatol</i> . 2011 May;38(5):835-45. Epub 2011 Jan 15. PubMed PMID: 21239748.	excl.
14: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. <i>Pharmacotherapy</i> . 2011 Jan;31(1):39-51. PubMed PMID: 21182357.	excl.
15: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. <i>Clin Exp Rheumatol</i> . 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: <i>Clin Exp Rheumatol</i> . 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.	excl.
16: Connock M, Tubeuf S, Malotki K, Uthman A, Round J, Bayliss S, Meads C, Moore D. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. <i>Health Technol Assess</i> . 2010 Oct;14(Suppl. 2):1-10. Review. PubMed PMID: 21047485.	excl.
17: Patel AM, Moreland LW. Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <i>Expert Rev Clin Immunol</i> . 2010 Nov;6(6):855-66. Review. PubMed PMID: 20979550.	excl.
18: Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, Danneskiold-Samsøe B, Christensen R. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. <i>Scand J Rheumatol</i> . 2011 Jan;40(1):1-7. Epub 2010 Oct 15. Review. PubMed PMID: 20950126.	excl.
19: Ramiro S, van Tubergen AM, Landewé RB. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. <i>Expert Rev Clin Immunol</i> . 2010 Sep;6(5):713-20. Review. PubMed PMID: 20828279.	excl.
20: van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijckens K, Keystone EC. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. <i>Arthritis Care Res (Hoboken)</i> . 2011 Jan;63(1):128-34. doi:10.1002/acr.20331. PubMed PMID: 20799264; PubMed Central PMCID: PMC3016460.	excl.: RCT sub-analysis
21: Goel N, Stephens S. Certolizumab pegol. <i>MAbs</i> . 2010 Mar-Apr;2(2):137-47. Review. PubMed PMID: 20190560; PubMed Central PMCID: PMC2840232.	excl.
22: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. <i>Drugs</i> . 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
23: Statkute L, Ruderman EM. Novel TNF antagonists for the treatment of rheumatoid arthritis. <i>Expert Opin Investig Drugs</i> . 2010 Jan;19(1):105-15. Review. PubMed PMID: 20001558.	excl.

References	Excl./Incl.
24: Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. <i>Arthritis Res Ther.</i> 2009;11(6):R170. Epub 2009 Nov 12. PubMed PMID: 19909548; PubMed Central PMCID:PMC3003523.	excl.: RCT sub-analysis
25: Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. <i>Arthritis Rheum.</i> 2009 Nov 15;61(11):1592-600. Erratum in: <i>Arthritis Rheum.</i> 2010 Oct;62(10):1514. PubMed PMID: 19877104.	excl.: RCT sub-analysis

### Search results for etanercept RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
1: Oderda GM, Balfe LM. Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis. <i>J Manag Care Pharm.</i> 2011 Nov-Dec;17(9 Suppl B):S19-24. PubMed PMID: 22073936.	excl.
2: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. <i>J Manag Care Pharm.</i> 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
3: Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. <i>Clin Pharmacol Ther.</i> 2011 Dec;90(6):828-35. doi: 10.1038/clpt.2011.256. Epub 2011 Nov 2. PubMed PMID: 22048227.	excl.
4: Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, Navarro-Millan I, Kavanaugh A. Predicting low disease activity and remission using early treatment response to antitumor necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. <i>Ann Rheum Dis.</i> 2012 Feb;71(2):206-12. Epub 2011 Oct 13. PubMed PMID: 21998118.	excl.: RCT sub-analysis
5: Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. <i>Keio J Med.</i> 2011;60(3):75-81. Review. PubMed PMID: 21979826.	excl.
6: Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. <i>Ann Rheum Dis.</i> 2012 Feb;71(2):225-30. Epub 2011 Sep 29. PubMed PMID: 21960560.	excl.
7: Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. <i>J Rheumatol.</i> 2011 Oct;38(10):2169-71. Epub 2011 Aug 1. PubMed PMID: 21807781.	excl.: open-label study
8: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. <i>Arthritis Res Ther.</i> 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
9: Brodsky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. <i>Orv Hetil.</i> 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
10: Keystone EC. Does anti-tumor necrosis factor- $\alpha$ therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. <i>J Rheumatol.</i> 2011 Aug;38(8):1552-62. Epub 2011 May 15. Review. PubMed PMID: 21572154.	excl.

References	Excl./Incl.
<p><b>11: Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011 Aug;38(8):1585-92. Epub 2011 May 15. PubMed PMID: 21572151.</b></p>	<p><b>Incl.: RCT</b></p>
<p>12: Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr Drugs. 2011 Jun 1;13(3):161-73. doi: 10.2165/11588140-000000000-00000. Review. PubMed PMID: 21500870.</p>	<p>excl.: JIA</p>
<p>13: Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1):269-74. PubMed PMID: 21496415.</p>	<p>excl.</p>
<p>14: Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011 Mar;15(14):1-278. Review. PubMed PMID: 21439251.</p>	<p>excl.</p>
<p>15: Roux CH, Breuil V, Valerio L, Amoretti N, Brocq O, Albert C, Grisot C, Allam Y, Chevalier P, Pradier C, Euller-Ziegler L. Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study. J Rheumatol. 2011 Jun;38(6):1009-11. Epub 2011 Mar 16. PubMed PMID: 21406499.</p>	<p>excl.: pilot study</p>
<p>16: Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, Maddox J, Weng HH, Wajdula J, Lin SL, Baumgartner SW. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011 Mar;10(3):289-300. PubMed PMID: 21369647.</p>	<p>excl.</p>
<p>17: Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibia J, Combe B. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol. 2011 May;38(5):835-45. Epub 2011 Jan 15. PubMed PMID: 21239748.</p>	<p>excl.</p>
<p>18: Liang DF, Huang F, Zhang JL, Yang CH, Zhang H, Guo JH, Zhao Z. [A randomized, single-blind, parallel, controlled clinical study on single intra-articular injection of etanercept in treatment of inflammatory knee arthritis]. Zhonghua Nei Ke Za Zhi. 2010 Nov;49(11):930-4. Chinese. PubMed PMID: 21211205.</p>	<p>excl.</p>
<p>19: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy. 2011 Jan;31(1):39-51. PubMed PMID: 21182357.</p>	<p>excl.</p>
<p>20: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 2010;128(5):309-10. Review. PubMed PMID: 21181074.</p>	<p>excl.</p>
<p>21: Silva LC, Ortigosa LC, Benard G. Anti-TNF-<math>\alpha</math> agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010 Nov;2(6):817-33. Review. PubMed PMID: 21091114.</p>	<p>excl.</p>
<p>22: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: Clin Exp Rheumatol. 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.</p>	<p>excl.</p>
<p>23: Shenoi S, Wallace CA. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs. 2010 Dec 1;12(6):367-77. doi: 10.2165/11532610-000000000-00000. Review. PubMed PMID: 21028916.</p>	<p>excl.: JIA</p>

References	Excl./Incl.
24: Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i> . 2011 Mar;63(3):373-82. doi: 10.1002/acr.20372. Epub 2010 Oct 18. PubMed PMID: 20957659.	excl: open-label study
25: van Luijn JC, Danz M, Bijlsma JW, Gribnau FW, Leufkens HG. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. <i>Scand J Rheumatol</i> . 2011 May;40(3):183-91. Epub 2010 Sep 21. PubMed PMID: 20858147.	excl.
26: Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. <i>Curr Eye Res</i> . 2010 Aug;35(8):751-6. PubMed PMID: 20673052.	excl.
27: Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. <i>JAMA</i> . 2010 Jul 28;304(4):452-60. Review. PubMed PMID: 20664046.	excl.
28: Gerlag DM, Hollis S, Layton M, Vencovský J, Szekanecz Z, Braddock M, Tak PP; ESCAPE Study Group. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis Rheum</i> . 2010 Nov;62(11):3154-60. doi: 10.1002/art.27652. PubMed PMID: 20662070.	excl.
29: Finckh A. Comparative effectiveness of rheumatoid arthritis therapies. <i>Curr Rheumatol Rep</i> . 2010 Oct;12(5):348-54. PubMed PMID: 20652775.	excl.
30: Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. <i>J Manag Care Pharm</i> . 2010 Jul-Aug;16(6):402-16. Review. PubMed PMID: 20635831.	excl.
<b>31: Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T; Japan Biological Agent Study Integrated Consortium. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Mod Rheumatol</i>. 2010 Dec;20(6):531-8. Epub 2010 Jun 24. PubMed PMID: 20574649.</b>	<b>incl.: RCT</b>
32: Lisbona MP, Maymó J, Perich J, Almirall M, Carbonell J. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. <i>Ann Rheum Dis</i> . 2010 Jun;69(6):1117-22. Epub 2010 May 6. PubMed PMID: 20448287.	excl.
33: Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, Wouters CH. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. <i>Rheumatology (Oxford)</i> . 2010 Aug;49(8):1550-8. Epub 2010 May 5. PubMed PMID: 20444859.	excl.: JIA
34: Abrahamyan L, Beyene J, Feng J, Chon Y, Willan AR, Schmeling H, Horneff G, Keystone EC, Feldman BM. Response times follow lognormal or gamma distribution in arthritis patients. <i>J Clin Epidemiol</i> . 2010 Dec;63(12):1363-9. PubMed PMID: 20430577.	excl.
35: Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome: potential therapeutic targets. <i>Ann Rheum Dis</i> . 2010 Jun;69(6):945-8. Epub 2010 Apr 21. PubMed PMID: 20410069; PubMed Central PMCID: PMC3044243.	excl.
36: Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. <i>Pharmacotherapy</i> . 2010 Apr;30(4):339-53. Review. PubMed PMID: 20334454.	excl.
37: Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. <i>Semin Arthritis Rheum</i> . 2010 Jun;39(6):425-41. Epub 2010 Mar 11. Review. PubMed PMID: 20223500.	excl.

References	Excl./Incl.
38: Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS, Freundlich B; Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. <i>Arthritis Rheum.</i> 2010 Mar;62(3):674-82. Erratum in: <i>Arthritis Rheum.</i> 2010 Oct;62(10):3005. PubMed PMID: 20187135.	Excl. RCT follow-up
39: Kavanaugh A, Keystone E, Feng J, Hooper M. Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA? <i>Rheumatology (Oxford).</i> 2010 Jun;49(6):1201-3. Epub 2010 Feb 24. PubMed PMID: 20181672.	excl.
40: Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R. [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009]. <i>Z Rheumatol.</i> 2010 Aug;69(6):561-7. German. PubMed PMID: 20174926.	excl.
41: Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. <i>Curr Dir Autoimmun.</i> 2010;11:180-210. Epub 2010 Feb 18. Review. PubMed PMID: 20173395.	excl.
42: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. <i>Drugs.</i> 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
43: De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, Galeazzi M. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. <i>Clin Rheumatol.</i> 2010 May;29(5):517-24. Epub 2010 Jan 16. PubMed PMID: 20082236.	excl.
44: Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. <i>J Rheumatol.</i> 2010 Feb;37(2):234-45. Epub 2010 Jan 15. Review. Erratum in: <i>J Rheumatol.</i> 2010 Mar;37(3):682. PubMed PMID: 20080922.	excl.
45: Ringold S, Chon Y, Singer NG. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis. <i>Arthritis Rheum.</i> 2009 Dec;60(12):3776-83. PubMed PMID: 19950286.	excl.: JIA
46: Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Res Ther.</i> 2009;11(6):R163. Epub 2009 Nov 3. Review. PubMed PMID: 19886983; PubMed Central PMCID: PMC3003527.	excl.
47: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. <i>CMAJ.</i> 2009 Nov 24;181(11):787-96. Epub 2009 Nov 2. Erratum in: <i>CMAJ.</i> 2010 May 18;182(8):806. PubMed PMID: 19884297; PubMed Central PMCID: PMC2780484.	excl.
48: Lukas C, van der Heijde D, Fatenajad S, Landewé R. Repair of erosions occurs almost exclusively in damaged joints without swelling. <i>Ann Rheum Dis.</i> 2010 May;69(5):851-5. Epub 2009 Oct 21. PubMed PMID: 19846407.	excl.
49: Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. <i>Ann Rheum Dis.</i> 2010 Jan;69(1):222-5. Epub . Erratum in: <i>Ann Rheum Dis.</i> 2011 Aug;70(8):1519. PubMed PMID: 19293160.	excl.: RCT sub-analysis

References	Excl./Incl.
50: Lukas C, Landewé R, Fatenejad S, van der Heijde D. Subtle changes in individual joints result in both positive and negative change scores in a patient: results from a clinical trial in patients with rheumatoid arthritis. <i>Ann Rheum Dis.</i> 2009 Nov;68(11):1691-5. Epub 2008 Nov 24. PubMed PMID: 19029169; PubMed Central PMCID: PMC2945936.	excl.: RCT sub-analysis

### Search results for golimumab RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
1: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. <i>J Manag Care Pharm.</i> 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
<b>2: Østergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, Rahman MU. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients. <i>Arthritis Rheum.</i> 2011 Dec;63(12):3712-22. doi: 10.1002/art.30592. PubMed PMID: 22127693.</b>	<b>incl.: RCT</b>
3: Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. <i>Clin Pharmacol Ther.</i> 2011 Dec;90(6):828-35. doi: 10.1038/clpt.2011.256. Epub 2011 Nov 2. PubMed PMID: 22048227.	excl.
4: Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. <i>Ann Rheum Dis.</i> 2012 Feb;71(2):225-30. Epub 2011 Sep 29. PubMed PMID: 21960560.	excl.
5: Emery P, van der Heijde D, Østergaard M, Conaghan PG, Genovese MC, Keystone EC, Fleischmann R, Hsia EC, Xu W, Xu S, Rahman MU. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. <i>Ann Rheum Dis.</i> 2011 Dec;70(12):2126-30. Epub 2011 Sep 16. PubMed PMID: 21926186; PubMed Central PMCID: PMC3212698.	excl.
6: Conaghan PG, Emery P, Østergaard M, Keystone EC, Genovese MC, Hsia EC, Xu W, Rahman MU. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. <i>Ann Rheum Dis.</i> 2011 Nov;70(11):1968-74. Epub 2011 Jul 21. PubMed PMID: 21784729; PubMed Central PMCID: PMC3184239.	excl. RCT sub-analysis
7: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. <i>Arthritis Res Ther.</i> 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
8: Brodzky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. <i>Orv Hetil.</i> 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
9: Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. <i>Curr Opin Rheumatol.</i> 2011 May;23(3):245-51. Review. PubMed PMID: 21427579.	excl.
10: Mackensen F, Lutz T. [Therapy for childhood uveitis: biologics: too often--too late?]. <i>Ophthalmologe.</i> 2011 Mar;108(3):213-21. Review. German. PubMed PMID: 21350869.	excl.

References	Excl./ Incl.
11: Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, Hsia EC, Xu W, Baratelle A, Beutler A, Rahman MU. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. <i>Arthritis Rheum.</i> 2011 May;63(5):1200-10. doi: 10.1002/art.30263. Erratum in: <i>Arthritis Rheum.</i> 2012 Apr;64(4):1045. PubMed PMID: 21305524.	excl.: RCT pooled analysis
12: Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. <i>J Rheumatol.</i> 2011 May;38(5):835-45. Epub 2011 Jan 15. PubMed PMID: 21239748.	excl.
13: Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor- $\alpha$ inhibitor. <i>Clin Ther.</i> 2010 Sep;32(10):1681-703. Review. PubMed PMID: 21194591.	excl.
14: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. <i>Pharmacotherapy.</i> 2011 Jan;31(1):39-51. PubMed PMID: 21182357.	excl.
15: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. <i>Clin Exp Rheumatol.</i> 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: <i>Clin Exp Rheumatol.</i> 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.	excl.
16: Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. <i>Arthritis Res Ther.</i> 2010;12(6):R211. Epub 2010 Nov 17. PubMed PMID: 21083889; PubMed Central PMCID: PMC3046519.	excl.: RCT sub- analysis
17: Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, Danneskiold-Samsøe B, Christensen R. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. <i>Scand J Rheumatol.</i> 2011 Jan;40(1):1-7. Epub 2010 Oct 15. Review. PubMed PMID: 20950126.	excl.
18: Voulgari PV. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>Expert Rev Clin Immunol.</i> 2010 Sep;6(5):721-33. Review. PubMed PMID: 20828280.	excl.
19: Hu C, Xu Z, Rahman MU, Davis HM, Zhou H. A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. <i>J Pharmacokinet Pharmacodyn.</i> 2010 Aug;37(4):309-21. Epub 2010 Jul 16. PubMed PMID: 20635122.	excl.
20: Hu C, Xu Z, Zhang Y, Rahman MU, Davis HM, Zhou H. Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. <i>J Clin Pharmacol.</i> 2011 May;51(5):639-48. Epub 2010 Jul 9. PubMed PMID: 20622199.	excl.
21: Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, Pazdur J, Bae SC, Palmer W, Xu S, Rahman MU. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. <i>Ann Rheum Dis.</i> 2010 Jun;69(6):1129-35. Epub 2010 May 5. Erratum in: <i>Ann Rheum Dis.</i> 2011 Jan;70(1):238-9. PubMed PMID: 20444749.	excl.: RCT open label ext.
22: Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. <i>J Rheumatol.</i> 2010 Jun;37(6):1096-104. Epub 2010 May 1. Review. PubMed PMID: 20436075.	excl.
23: Campas-Moya C. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>Drugs Today (Barc).</i> 2010 Jan;46(1):13-22. Review. PubMed PMID: 20200692.	excl.

References	Excl./Incl.
24: Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010 Mar;25(1):1-17. Epub 2010 Feb 26. Review. PubMed PMID: 20195397; PubMed Central PMCID: PMC2829405.	excl.
<b>25: Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010 Apr;62(4):917-28. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3130. PubMed PMID: 20131276.</b>	<b>incl.: RCT</b>
26: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
27: Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008341. Review. PubMed PMID: 20091667.	excl.
28: Statkute L, Ruderman EM. Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2010 Jan;19(1):105-15. Review. PubMed PMID: 20001558.	excl.

#### Search results for infliximab RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
1: Oderda GM, Balfe LM. Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis. J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S19-24. PubMed PMID: 22073936.	excl.
2: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
3: Dirven L, Visser K, Klarenbeek NB, Ewals JA, Han KH, Peeters AJ, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression. Scand J Rheumatol. 2012 Feb;41(1):15-9. Epub 2011 Nov 21. PubMed PMID: 22103436.	excl.
4: Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011 Dec;90(6):828-35. doi: 10.1038/clpt.2011.256. Epub 2011 Nov 2. PubMed PMID: 22048227.	excl.
5: Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012 Feb;71(2):225-30. Epub 2011 Sep 29. PubMed PMID: 21960560.	excl.
6: Schiff M, Keiserman M, Coddling C, Songcharoen S, Berman A, Nayiager S, Saldate C, Aranda R, Becker JC, Nys M, le Bars M, Reed DM, Poncet C, Dougados M. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2011 Nov;70(11):2003-7. Epub 2011 Sep 12. PubMed PMID: 21914628; PubMed Central PMCID: PMC3184243.	excl.: RCT open label follow up



References	Excl./Incl.
7: Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i> . 2011 Jul;63(7):929-36. doi: 10.1002/acr.20497. PubMed PMID: 21717596.	excl.: JIA
8: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. <i>Arthritis Res Ther</i> . 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
9: Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. <i>Arthritis Res Ther</i> . 2011 May 25;13 Suppl 1:S3. Review. PubMed PMID: 21624182; PubMed Central PMCID: PMC3123964.	excl.
10: Smolen JS, Emery P. Infliximab: 12 years of experience. <i>Arthritis Res Ther</i> . 2011 May 25;13 Suppl 1:S2. Review. PubMed PMID: 21624181; PubMed Central PMCID: PMC3123963.	excl.
11: Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. <i>Ann Rheum Dis</i> . 2011 Sep;70(9):1605-12. Epub 2011 May 28. PubMed PMID: 21623000.	excl.: JIA
12: Brodszky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. <i>Orv Hetil</i> . 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
13: Keystone EC. Does anti-tumor necrosis factor- $\alpha$ therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. <i>J Rheumatol</i> . 2011 Aug;38(8):1552-62. Epub 2011 May 15. Review. PubMed PMID: 21572154.	excl.
14: Gonzalez-Gay MA, Gonzalez-Juanatey C, Miranda-Fillooy JA, Martin J, Garcia-Unzueta MT, Llorca J. Response to 'Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months'. <i>Arthritis Res Ther</i> . 2011 Apr 27;13(2):404. PubMed PMID: 21542887; PubMed Central PMCID: PMC3132047.	excl.
15: van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. <i>Ann Rheum Dis</i> . 2011 Aug;70(8):1389-94. Epub 2011 Apr 24. PubMed PMID: 21515916.	excl.: RCT sub-analysis
16: Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. <i>Paediatr Drugs</i> . 2011 Jun 1;13(3):161-73. doi: 10.2165/11588140-000000000-00000. Review. PubMed PMID: 21500870.	excl.
<b>17: Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. <i>Ann Rheum Dis</i>. 2011 Jul;70(7):1208-15. Epub 2011 Apr 8. PubMed PMID: 21478189; PubMed Central PMCID: PMC3103666.</b>	<b>incl.: RCT</b>
18: Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. <i>Health Technol Assess</i> . 2011 Mar;15(14):1-278. Review. PubMed PMID: 21439251.	excl.

References	Excl./Incl.
19: Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW, Dijkmans BA, Allaart CF. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. <i>Ann Rheum Dis</i> . 2011 Jun;70(6):1039-46. Epub 2011 Mar 17. PubMed PMID: 21415052.	excl.: RCT open label follow up
20: Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, Li ZG. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. <i>J Rheumatol</i> . 2011 May;38(5):821-7. Epub 2011 Mar 1. PubMed PMID: 21362762.	excl.
21: Mackensen F, Lutz T. [Therapy for childhood uveitis: biologics: too often--too late?]. <i>Ophthalmologe</i> . 2011 Mar;108(3):213-21. Review. German. PubMed PMID: 21350869.	excl.
22: Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. <i>J Rheumatol</i> . 2011 May;38(5):835-45. Epub 2011 Jan 15. PubMed PMID: 21239748.	excl.
23: Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. <i>Arthritis Rheum</i> . 2011 Jan;63(1):43-52. doi: 10.1002/art.27740. PubMed PMID: 21204103.	excl.
24: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. <i>Pharmacotherapy</i> . 2011 Jan;31(1):39-51. PubMed PMID: 21182357.	excl.
25: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. <i>Sao Paulo Med J</i> . 2010;128(5):309-10. Review. PubMed PMID: 21181074.	excl.
26: Silva LC, Ortigosa LC, Benard G. Anti-TNF- $\alpha$ agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. <i>Immunotherapy</i> . 2010 Nov;2(6):817-33. Review. PubMed PMID: 21091114.	excl.
27: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. <i>Clin Exp Rheumatol</i> . 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: <i>Clin Exp Rheumatol</i> . 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.	excl.
28: Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, van Groenendael JH, Han KH, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. <i>Ann Rheum Dis</i> . 2011 Feb;70(2):315-9. Epub 2010 Nov 10. PubMed PMID: 21068104.	excl.: RCT sub-analysis
29: Sheno S, Wallace CA. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. <i>Paediatr Drugs</i> . 2010 Dec 1;12(6):367-77. doi: 10.2165/11532610-000000000-00000. Review. PubMed PMID: 21028916.	excl.: JIA
30: Engvall IL, Tengstrand B, Brismar K, Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. <i>Arthritis Res Ther</i> . 2010;12(5):R197. Epub 2010 Oct 21. PubMed PMID: 20964833; PubMed Central PMCID: PMC2991034.	excl.
31: Güler-Yüksel M, Allaart CF, Watt I, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Schaardenburg D, van Krugten MV, Dijkmans BA, Huizinga TW, Lems WF, Kloppenburg M. Treatment with TNF- $\alpha$ inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. <i>Osteoarthritis Cartilage</i> . 2010 Oct;18(10):1256-62. Epub 2010 Aug 5. PubMed PMID: 20691795.	excl.

References	Excl./Incl.
32: Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S, Sarzi-Puttini P. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. <i>Autoimmun Rev.</i> 2010 Oct;9(12):835-9. Epub 2010 Jul 30. PubMed PMID: 20678592.	excl.
33: Aletaha D. Therapy: Challenging the course of RA: time for drug-free remission? <i>Nat Rev Rheumatol.</i> 2010 Aug;6(8):442-3. PubMed PMID: 20676124.	excl.
34: Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. <i>Curr Eye Res.</i> 2010 Aug;35(8):751-6. PubMed PMID: 20673052.	excl.
35: Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. <i>JAMA.</i> 2010 Jul 28;304(4):452-60. Review. PubMed PMID: 20664046.	excl.
36: Finckh A. Comparative effectiveness of rheumatoid arthritis therapies. <i>Curr Rheumatol Rep.</i> 2010 Oct;12(5):348-54. PubMed PMID: 20652775.	excl.
37: Klarenbeek NB, Güler-Yüksel M, van der Heijde DM, Hulsmans HM, Kerstens PJ, Molenaar TH, de Sonnaville PB, Huizinga TW, Dijkmans BA, Allaart CF. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. <i>Ann Rheum Dis.</i> 2010 Dec;69(12):2107-13. Epub 2010 Jul 7. PubMed PMID: 20610442.	excl.
38: Shen H, Xia L, Lu J, Xiao W. Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. <i>J Investig Med.</i> 2010 Oct;58(7):905-8. PubMed PMID: 20601897.	excl.
39: Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? <i>J Immunol.</i> 2010 Jul 15;185(2):791-4. PubMed PMID: 20601610.	excl.
40: Bejarano V, Conaghan PG, Quinn MA, Saleem B, Emery P. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. <i>Rheumatology (Oxford).</i> 2010 Oct;49(10):1971-4. Epub 2010 Jul 1. PubMed PMID: 20595536.	excl.
41: van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, Tak PP, Verweij CL. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. <i>Genes Immun.</i> 2010 Dec;11(8):622-9. Epub 2010 Jun 17. PubMed PMID: 20555356.	excl.
42: Scheinberg M, Guedes-Barbosa LS, Manguiera C, Rosseto EA, Mota L, Oliveira AC, Lima RA. Yellow fever revaccination during infliximab therapy. <i>Arthritis Care Res (Hoboken).</i> 2010 Jun;62(6):896-8. PubMed PMID: 20535801.	excl.
43: Tsuzaka K, Itami Y, Takeuchi T, Shinozaki N, Morishita T. ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis. <i>J Rheumatol.</i> 2010 Jul;37(7):1454-60. Epub 2010 Jun 1. PubMed PMID: 20516019.	excl.
44: Ringold S, Bittner R, Neogi T, Wallace CA, Singer NG. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. <i>Arthritis Care Res (Hoboken).</i> 2010 Aug;62(8):1095-102. PubMed PMID: 20506561.	excl.
45: Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Roday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. <i>Ann Rheum Dis.</i> 2010 Jul;69(7):1333-7. Epub 2010 May 24. PubMed PMID: 20498212.	excl.: RCT sub-analysis

References	Excl./Incl.
46: Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. <i>Clin Exp Rheumatol</i> . 2010 Mar-Apr;28(2):254-7. Epub 2010 May 13. PubMed PMID: 20483049.	excl.
47: Güler-Yüksel M, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van der Kooij SM, Gerards AH, Roday HK, Huizinga TW, Dijkmans BA, Allaart CF, Lems WF. Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. <i>Arthritis Res Ther</i> . 2010;12(3):R96. Epub 2010 May 20. PubMed PMID: 20482894; PubMed Central PMCID: PMC2911882.	excl.
48: Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, Speyer I, de Vries-Bouwstra JK, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. <i>Ann Rheum Dis</i> . 2010 Jul;69(7):1342-5. Epub 2010 May 14. PubMed PMID: 20472597.	excl.: RCT sub-analysis
<b>49: Gao GH, Li J, Xie HW, Lü Z. [Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis]. <i>Nan Fang Yi Ke Da Xue Xue Bao</i>. 2010 Apr;30(4):724-6. Chinese. PubMed PMID: 20423835.</b>	<b>incl.: RCT</b>
50: Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome: potential therapeutic targets. <i>Ann Rheum Dis</i> . 2010 Jun;69(6):945-8. Epub 2010 Apr 21. PubMed PMID: 20410069; PubMed Central PMCID: PMC3044243.	excl.
51: Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. <i>Pharmacotherapy</i> . 2010 Apr;30(4):339-53. Review. PubMed PMID: 20334454.	excl.
52: Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Xu S, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. <i>Ann Rheum Dis</i> . 2010 Apr;69(4):718-22. Erratum in: <i>Ann Rheum Dis</i> . 2011 Nov;70(11):2060. PubMed PMID: 20237125; PubMed Central PMCID: PMC2946101.	excl.: JIA
53: Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. <i>Semin Arthritis Rheum</i> . 2010 Jun;39(6):425-41. Epub 2010 Mar 11. Review. PubMed PMID: 20223500.	excl.
54: Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. <i>Korean J Intern Med</i> . 2010 Mar;25(1):1-17. Epub 2010 Feb 26. Review. PubMed PMID: 20195397; PubMed Central PMCID: PMC2829405.	excl.
55: Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R. [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009]. <i>Z Rheumatol</i> . 2010 Aug;69(6):561-7. German. PubMed PMID: 20174926.	excl.

References	Excl./Incl.
56: Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. <i>Curr Dir Autoimmun.</i> 2010;11:180-210. Epub 2010 Feb 18. Review. PubMed PMID: 20173395.	excl.
57: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. <i>Drugs.</i> 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
58: Schiff M, Bessette L. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. <i>Clin Rheumatol.</i> 2010 Jun;29(6):583-91. Epub 2010 Jan 23. Review. PubMed PMID: 20099018.	excl.
59: De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, Galeazzi M. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. <i>Clin Rheumatol.</i> 2010 May;29(5):517-24. Epub 2010 Jan 16. PubMed PMID: 20082236.	excl.
60: Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Res Ther.</i> 2009;11(6):R163. Epub 2009 Nov 3. Review. PubMed PMID: 19886983; PubMed Central PMCID: PMC3003527.	excl.
61: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. <i>CMAJ.</i> 2009 Nov 24;181(11):787-96. Epub 2009 Nov 2. Erratum in: <i>CMAJ.</i> 2010 May 18;182(8):806. PubMed PMID: 19884297; PubMed Central PMCID: PMC2780484.	excl.
62: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. <i>Cochrane Database Syst Rev.</i> 2009 Oct 7;(4):CD007848. Review. PubMed PMID: 19821440.	excl.
63: Köller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. <i>Rheumatology (Oxford).</i> 2009 Dec;48(12):1575-80. Epub 2009 Oct 7. PubMed PMID: 19812228.	excl.
64: Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, Pontarolo R. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. <i>Clin Rheumatol.</i> 2009 Dec;28(12):1365-73. Epub 2009 Sep 22. Review. PubMed PMID: 19771491.	excl.

### Search results for rituximab RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
1: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. <i>J Manag Care Pharm.</i> 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
2: Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. <i>Best Pract Res Clin Rheumatol.</i> 2011 Aug;25(4):535-48. doi: 10.1016/j.berh.2011.10.005. Review. PubMed PMID: 22137923.	excl.
3: Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. <i>Arthritis Rheum.</i> 2011 Dec;63(12):3692-701. doi: 10.1002/art.30599. PubMed PMID: 22127692.	excl.

References	Excl./ Incl.
4: Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. <i>Arthritis Rheum.</i> 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596. PubMed PMID: 22127691.	excl.: RCT sub- analysis
5: Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. <i>Ann Rheum Dis.</i> 2012 Mar;71(3):351-7. Epub 2011 Oct 19. PubMed PMID: 22012969.	excl.: RCT sub- analysis
6: Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. <i>Sci Transl Med.</i> 2011 Sep 21;3(101):101ra92. PubMed PMID: 21937757.	excl.
7: Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Müller-Ladner U, Gaylis NB, Williams S, Reynard M, Tyrrell H. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. <i>Rheumatology (Oxford).</i> 2011 Dec;50(12):2223-32. Epub 2011 Sep 16. PubMed PMID: 21926153; PubMed Central PMCID: PMC3222846.	excl.
8: Martín Mola E, Hernández B, García-Arias M, Alvaro-Gracia JM, Balsa A, Reino JG, Marengo de la Fuente JL, Martínez-Taboada V, Ivorra JA, Sanmartí R; el grupo de Expertos en Rituximab. [Consensus on the Use of Rituximab in Rheumatoid Arthritis. A document with evidence-based recommendations. Grupo de Expertos en Rituximab. ]. <i>Reumatol Clin.</i> 2011 Jan-Feb;7(1):30-44. Epub 2010 Dec 17. Spanish. PubMed PMID: 21794777.	excl.
9: Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. <i>Autoimmun Rev.</i> 2011 Nov;11(1):35-9. Epub 2011 Jul 13. Review. PubMed PMID: 21763790.	excl.
10: Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. <i>Clin Ther.</i> 2011 Jun;33(6):679-707. Review. PubMed PMID: 21704234.	excl.
11: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. <i>Arthritis Res Ther.</i> 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
12: Brodsky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. <i>Orv Hetil.</i> 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
<b>13: Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. <i>Arthritis Care Res (Hoboken).</i> 2011 May;63(5):711-20. doi: 10.1002/acr.20419. PubMed PMID: 21557525.</b>	<b>incl: RCT</b>
14: Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. <i>Rheumatology (Oxford).</i> 2012 Jan;51(1):60-8. Epub 2011 Apr 22. Review. PubMed PMID: 21515629.	excl.
15: Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. <i>Health Technol Assess.</i> 2011 Mar;15(14):1-278. Review. PubMed PMID: 21439251.	excl.

References	Excl./ Incl.
16: Behrens F, Koehm M, Burkhardt H. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. <i>Curr Opin Rheumatol</i> . 2011 May;23(3):282-7. Review. PubMed PMID: 21427581.	excl.
17: Brinkman IH, van de Laar MA, Jansen TL, van Roon EN. The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. <i>Expert Opin Drug Saf</i> . 2011 Sep;10(5):715-26. Epub 2011 Mar 15. Review. PubMed PMID: 21401437.	excl.
18: van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JW, van den Berg WB, Joosten LA. The anti-CD20 antibody rituximab reduces the Th17 cell response. <i>Arthritis Rheum</i> . 2011 Jun;63(6):1507-16. doi: 10.1002/art.30314. PubMed PMID: 21400475.	excl.
19: Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? <i>Curr Opin Rheumatol</i> . 2011 May;23(3):288-92. Review. PubMed PMID: 21378570.	excl.
20: Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. <i>Arthritis Rheum</i> . 2011 Apr;63(4):933-8. doi: 10.1002/art.30233. PubMed PMID: 21225699.	excl.
21: Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK, Kallenberg CG, Bootsma H. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. <i>Arthritis Rheum</i> . 2011 Apr;63(4):1116-23. doi: 10.1002/art.30236. PubMed PMID: 21225693.	excl.
22: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. <i>Pharmacotherapy</i> . 2011 Jan;31(1):39-51. PubMed PMID: 21182357.	excl.
23: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. <i>Sao Paulo Med J</i> . 2010;128(5):309-10. Review. PubMed PMID: 21181074.	excl.
24: Conway R, Carey JJ. Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). <i>Rheumatology (Oxford)</i> . 2011 Mar;50(3):631-2; author reply 632-3. Epub 2010 Dec 20. PubMed PMID: 21172927.	excl.
25: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. <i>Clin Exp Rheumatol</i> . 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: <i>Clin Exp Rheumatol</i> . 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.	excl.
26: Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, Danneskiold-Samsøe B, Christensen R. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. <i>Scand J Rheumatol</i> . 2011 Jan;40(1):1-7. Epub 2010 Oct 15. Review. PubMed PMID: 20950126.	excl.
<b>27: Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hesse E, Chen A, Tyrrell H, Shaw TM; IMAGE Investigators. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. <i>Ann Rheum Dis</i>. 2011 Jan;70(1):39-46. Epub 2010 Oct 11. PubMed PMID: 20937671.</b>	<b>Incl.: RCT</b>
28: Mariette X, Gottenberg JE. Pathogenesis of Sjögren's syndrome and therapeutic consequences. <i>Curr Opin Rheumatol</i> . 2010 Sep;22(5):471-7. Review. PubMed PMID: 20671520.	excl.

References	Excl./ Incl.
29: Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. <i>JAMA</i> . 2010 Jul 28;304(4):452-60. Review. PubMed PMID: 20664046.	excl.
30: Covelli M, Sarzi-Puttini P, Atzeni F, Macchioni P. Safety of rituximab in rheumatoid arthritis. <i>Reumatismo</i> . 2010 Apr-Jun;62(2):101-6. Review. PubMed PMID: 20657886.	excl.
31: Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? <i>Autoimmun Rev</i> . 2010 Oct;9(12):801-3. Epub 2010 Jul 23. Review. PubMed PMID: 20656069.	excl.
32: Sokolović S, Kasumagić S, Mackić-Durović M, Aganović-Musinović I. The impact of Rituximab therapy on the chromosomes of patients with Rheumatoid arthritis. <i>Bosn J Basic Med Sci</i> . 2010 May;10(2):121-4. PubMed PMID: 20507292.	excl.
33: Devauchelle-Pensec V, Cagnard N, Pers JO, Youinou P, Saraux A, Chiochia G. Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab. <i>Arthritis Rheum</i> . 2010 Aug;62(8):2262-71. PubMed PMID: 20506202.	excl.
<b>34: Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). <i>Ann Rheum Dis</i>. 2010 Sep;69(9):1629-35. Epub 2010 May 20. Erratum in: <i>Ann Rheum Dis</i>. 2011 Aug;70(8):1519. PubMed PMID: 20488885; PubMed Central PMCID: PMC2938895.</b>	<b>Incl.: RCT</b>
35: Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. <i>Rheumatol Int</i> . 2011 Nov;31(11):1493-9. Epub 2010 May 16. Review. PubMed PMID: 20473756.	excl.
<b>36: Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, Collinson N, Shaw TM; MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). <i>Rheumatology (Oxford)</i>. 2010 Sep;49(9):1683-93. Epub 2010 May 12. PubMed PMID: 20463186; PubMed Central PMCID: PMC2919195.</b>	<b>Incl.: RCT</b>
37: Saraux A. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome. <i>Autoimmun Rev</i> . 2010 Jul;9(9):609-14. Epub 2010 May 7. Review. PubMed PMID: 20452466.	excl.
38: Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, Cravets M, Shaw T, Hagerty D. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. <i>Ann Rheum Dis</i> . 2010 Jun;69(6):1158-61. Epub 2010 May 3. Erratum in: <i>Ann Rheum Dis</i> . 2011 Aug;70(8):1519. PubMed PMID: 20439295; PubMed Central PMCID: PMC2935326.	excl.: RCT sub- analysis
39: Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. <i>Semin Arthritis Rheum</i> . 2010 Jun;39(6):425-41. Epub 2010 Mar 11. Review. PubMed PMID: 20223500.	excl.
<b>40: Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. <i>J Rheumatol</i>. 2010 May;37(5):917-27. Epub 2010 Mar 1. PubMed PMID: 20194448.</b>	<b>Incl.: RCT</b>



References	Excl./Incl.
41: Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. <i>Curr Opin Rheumatol</i> . 2010 May;22(3):321-9. Review. PubMed PMID: 20190641.	excl.
42: Jacobi AM, Dörner T. Current aspects of anti-CD20 therapy in rheumatoid arthritis. <i>Curr Opin Pharmacol</i> . 2010 Jun;10(3):316-21. Epub 2010 Feb 26. Review. PubMed PMID: 20189875.	excl.
43: Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheum</i> . 2010 Apr;62(4):960-8. PubMed PMID: 20131246.	excl.
44: van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. <i>J Rheumatol</i> . 2010 Mar;37(3):558-67. Epub 2010 Jan 28. Erratum in: <i>J Rheumatol</i> . 2010 Oct;37(10):2198. PubMed PMID: 20110520.	excl.: RCT sub-analysis
45: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. <i>Drugs</i> . 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
46: Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Coddling C, Trzaskoma B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. <i>Arthritis Rheum</i> . 2010 Jan;62(1):64-74. PubMed PMID: 20039397.	excl.
47: Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Res Ther</i> . 2009;11(6):R163. Epub 2009 Nov 3. Review. PubMed PMID: 19886983; PubMed Central PMCID: PMC3003527.	excl.
48: Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. <i>CMAJ</i> . 2009 Nov 24;181(11):787-96. Epub 2009 Nov 2. Erratum in: <i>CMAJ</i> . 2010 May 18;182(8):806. PubMed PMID: 19884297; PubMed Central PMCID: PMC2780484.	excl.
49: Korhonen R, Moilanen E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. <i>Basic Clin Pharmacol Toxicol</i> . 2010 Jan;106(1):13-21. Epub 2009 Jul 22. Review. PubMed PMID: 19686542.	excl.
50: Schmidt WA, Schicke B, Krause A, Wernicke D. [How effective is rituximab in rheumatoid arthritis?: lessons learned from clinical practice]. <i>Z Rheumatol</i> . 2010 Jun;69(4):349-55. German. PubMed PMID: 19449016.	excl.

### Search results for tocilizumab RCTs and selection of studies (01.11.2009-31.03.2012)

References	Excl./Incl.
1: Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managedcare professionals. <i>J Manag Care Pharm</i> . 2011 Nov-Dec;17(9 Suppl B):S14-8. Review. PubMed PMID: 22073935.	excl.
2: Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. <i>Atherosclerosis</i> . 2011 Dec;219(2):734-6. Epub 2011 Sep 16. PubMed PMID: 21968316.	excl.

References	Excl./ Incl.
<b>3: Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb;71(2):198-205. Epub 2011 Sep 26.PubMed PMID: 21949007.</b>	<b>incl.: RCT</b>
4: Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011 Oct;38(10):2169-71. Epub 2011 Aug 1. PubMed PMID: 21807781.	excl.
5: Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5. Review. PubMed PMID: 21624184; PubMed Central PMCID: PMC3123966.	excl.
6: Brodsky V. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. Orv Hetil. 2011 Jun 5;152(23):919-28. Hungarian. PubMed PMID: 21592952.	excl.
7: Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford). 2012 Jan;51(1):60-8. Epub 2011 Apr 22. Review. PubMed PMID: 21515629.	excl.
8: Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr Drugs. 2011 Jun 1;13(3):161-73. doi: 10.2165/11588140-000000000-00000. Review. PubMed PMID: 21500870.	excl.
9: Mircic M, Kavanaugh A. Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis. Exp Cell Res. 2011 May 15;317(9):1286-92. Epub 2011 Mar 22. Review. PubMed PMID: 21439276.	excl.
10: Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011 May;89(5):735-40. Epub 2011 Mar 23. Erratum in: Clin Pharmacol Ther. 2011 Sep;90(3):479. Dosage error in article text. PubMed PMID: 21430660.	excl.
11: Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol. 2011 May;23(3):245-51. Review. PubMed PMID: 21427579.	excl.
12: Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol. 2011 May;23(3):273-7. Review. PubMed PMID: 21427577.	excl.
13: Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian meta-analysis. J Rheumatol. 2011 May;38(5):835-45. Epub 2011 Jan 15. PubMed PMID: 21239748.	excl.
14: Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011 Jan;63(1):43-52. doi: 10.1002/art.27740. PubMed PMID: 21204103.	excl.
15: Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biological therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy. 2011 Jan;31(1):39-51. PubMed PMID: 21182357.	excl.
16: Rau R. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: Clin Exp Rheumatol. 2011 Mar-Apr;29(2):364. PubMed PMID: 21044435.	excl.
17: Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011 Mar;50(3):552-62. Epub 2010 Nov 14. Review. PubMed PMID: 21078627.	excl.
18: Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2010 Nov;6(6):843-54. Review. PubMed PMID: 20979549.	excl.

References	Excl./ Incl.
19: Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther. 2010 Aug;32(9):1597-609. PubMed PMID: 20974317.	excl.
20: Woodrick R, Ruderman EM. Anti-interleukin-6 therapy in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2010;68(3):211-7. Review. PubMed PMID: 20969554.	excl.
21: Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011 Jan;38(1):10-20. Epub 2010 Oct 15. Review. PubMed PMID: 20952462.	excl.
22: Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, Danneskiold-Samsøe B, Christensen R. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011 Jan;40(1):1-7. Epub 2010 Oct 15. Review. PubMed PMID: 20950126.	excl.
23: Yokota S, Kishimoto T. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2010 Sep;6(5):735-43. Review. PubMed PMID: 20828281.	excl.
24: Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S, Sarzi-Puttini P. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev. 2010 Oct;9(12):835-9. Epub 2010 Jul 30. PubMed PMID: 20678592.	excl.
25: Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm. 2010 Jul-Aug;16(6):402-16. Review. PubMed PMID: 20635831.	excl.
26: Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010 Dec;20(6):539-47. Epub 2010 Jul 10. PubMed PMID: 20617358; PubMed Central PMCID: PMC2999727.	excl.: RCT sub-analysis
27: Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD008331. Review. PubMed PMID: 20614469.	excl.
28: Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011 Feb;21(1):10-5. Epub 2010 Jun 24. PubMed PMID: 20574648; PubMed Central PMCID: PMC3036807.	excl.: RCT sub-analysis
29: Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol. 2010 Mar;6(2):189-95. PubMed PMID: 20402381.	excl.
30: Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010 Jun;39(6):425-41. Epub 2010 Mar 11. Review. PubMed PMID: 20223500.	excl.
31: McCluggage LK, Hussar DA. New drugs: Ustekinumab, tocilizumab, and telavancin hydrochloride. J Am Pharm Assoc (2003). 2010 Mar-Apr 1;50(2):324-7. PubMed PMID: 20199969.	excl.
32: Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010 Mar;25(1):1-17. Epub 2010 Feb 26. Review. PubMed PMID: 20195397; PubMed Central PMCID: PMC2829405.	excl.

References	Excl./ Incl.
33: Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. <i>Curr Opin Rheumatol.</i> 2010 May;22(3):321-9. Review. PubMed PMID: 20190641.	excl.
34: Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. <i>Drugs.</i> 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review. PubMed PMID: 20108988.	excl.
35: Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. <i>J Clin Pharmacol.</i> 2010 Jul;50(7):754-66. Epub 2010 Jan 23. PubMed PMID: 20097931.	excl.
36: Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. <i>Arthritis Rheum.</i> 2010 Jan;62(1):33-43. PubMed PMID: 20039425.	excl.: RCT sub- analysis
37: An MM, Zou Z, Shen H, Zhang JD, Cao YB, Jiang YY. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. <i>Eur J Clin Pharmacol.</i> 2010 Jan;66(1):49-59. Epub 2009 Nov 21. PubMed PMID: 19936725.	excl.
38: Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Res Ther.</i> 2009;11(6):R163. Epub 2009 Nov 3. Review. PubMed PMID: 19886983; PubMed Central PMCID: PMC3003527.	excl.
39: Hirabayashi Y, Ishii T, Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. <i>Rheumatol Int.</i> 2010 Jun;30(8):1041-8. Epub 2009 Aug 22. PubMed PMID: 19701637; PubMed Central PMCID: PMC2877340.	excl.
<b>40: Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. <i>Ann Rheum Dis.</i> 2010 Jan;69(1):88-96. Epub . PubMed PMID: 19297346.</b>	<b>incl.: RCT</b>